Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $113360.0.

  • bioAffinity Technologies' Depreciation & Amortization (CF) fell 2507.5% to $113360.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $534809.0, marking a year-over-year decrease of 1098.27%. This contributed to the annual value of $605637.0 for FY2024, which is 14265.08% up from last year.
  • Per bioAffinity Technologies' latest filing, its Depreciation & Amortization (CF) stood at $113360.0 for Q3 2025, which was down 2507.5% from $113229.0 recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Depreciation & Amortization (CF) high stood at $154588.0 for Q1 2025, and its period low was $773.0 during Q3 2022.
  • In the last 4 years, bioAffinity Technologies' Depreciation & Amortization (CF) had a median value of $113229.0 in 2025 and averaged $83105.9.
  • As far as peak fluctuations go, bioAffinity Technologies' Depreciation & Amortization (CF) surged by 734747.74% in 2023, and later plummeted by 2507.5% in 2025.
  • Quarter analysis of 4 years shows bioAffinity Technologies' Depreciation & Amortization (CF) stood at $7330.0 in 2022, then soared by 1929.84% to $148787.0 in 2023, then increased by 3.26% to $153632.0 in 2024, then decreased by 26.21% to $113360.0 in 2025.
  • Its Depreciation & Amortization (CF) was $113360.0 in Q3 2025, compared to $113229.0 in Q2 2025 and $154588.0 in Q1 2025.